TRIM21 and rheumatoid arthritis: Patients with dual-positive Ro52+/Ro60+ antibodies exhibited the highest risk for developing D2T-RA (OR 3.61, 95% CI 1.39–10.00, p = 0.009), followed by those with Ro52+/Ro60− antibodies (OR 3.23, 95% CI 0.96–10.50, p = 0.058).